Phase 1/2a Study of ANPD001 in Parkinson Disease
Public ClinicalTrials.gov record NCT06344026. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1/2a Dose Escalation Study of ANPD001 in Sporadic Parkinson Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This clinical trial is designed to test the safety and tolerability of injecting ANPD001 cells that will mature into dopamine-producing cells into the brain of participants with Parkinson Disease. All participants will have ANPD001 cells manufactured from their own previously collected cells.
Study identification
- NCT ID
- NCT06344026
- Recruitment status
- Enrolling by invitation
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 9 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 23, 2024 (Actual)
- Primary completion
- Mar 30, 2027 (Estimated)
- Completion
- Apr 30, 2030 (Estimated)
- Last update posted
- May 14, 2026
2024 – 2030
United States locations
- U.S. sites
- 9
- U.S. states
- 5
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona - Banner Health | Tucson | Arizona | 85724 | — |
| Scripps Health | La Jolla | California | 92037 | — |
| University of California, Los Angeles | Los Angeles | California | 90095 | — |
| University of California, Irvine | Orange | California | 92868 | — |
| University of California, San Diego | San Diego | California | 92037 | — |
| University of California, San Francisco | San Francisco | California | 94143 | — |
| University of Colorado | Aurora | Colorado | 80045 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Feinstein Institutes | Manhasset | New York | 11030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06344026, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 14, 2026 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06344026 live on ClinicalTrials.gov.